Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 465-471, 2007. First published February 1, 2007; 10.1373/clinchem.2006.077297
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 077297.Supplemental Data
Right arrow A correction has been published
Right arrow All Versions of this Article:
clinchem.2006.077297v1
53/3/465    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, J.
Right arrow Articles by Chen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, J.
Right arrow Articles by Chen, T.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Animal Clinical Chemistry
Right arrow Clinical Immunology
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2007;53:465-471.)
© 2007 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Identification of a New Metabolite of Astilbin, 3'-O-Methylastilbin, and Its Immunosuppressive Activity against Contact Dermatitis

Jianming Guo1, Feng Qian1, Jianxin Li2, Qiang Xu1,a and Ting Chen1,a

1 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, and 2 Key Laboratory of Analytical Chemistry for Life Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China.

aAddress correspondence to these authors at: School of Life Sciences, Nanjing University, 22 Han Kou Rd., Nanjing 210093, China. Fax 86-25-8359-7620; e-mail molpharm{at}163.com.

Background: Astilbin is a flavonoid isolated from the rhizome of Smilax glabra. In a previous study, we revealed its unique immunosuppressive activity, a selective inhibition against activated T lymphocytes. This characteristic of astilbin is beneficial for the treatment of human immune diseases.

Methods: We incubated astilbin with rat liver microsomal/cytosolic fractions and isolated the metabolite of astilbin, which was fully characterized by mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. We administered astilbin orally via a gastric tube to rats at 0.22 mmol/kg and collected whole blood samples after 30 min and urine samples after 0 to 12 h. We applied HPLC and liquid chromatography/MS to measure the metabolite in the samples, and we assayed cytokine expression by reverse-transcription PCR.

Results: After incubation of astilbin with rat liver microsomal/cytosolic fractions, we detected a new metabolite of astilbin and isolated it from the culture solution. We characterized this metabolite by MS and NMR techniques as 3'-O-methylated astilbin. We detected the metabolite in both blood and urine samples after oral administration of astilbin, and the metabolite inhibited picryl chloride–induced ear swelling in mice and suppressed the expression of tumor necrosis factor-{alpha} and interferon-{gamma}, similarly to astilbin.

Conclusion: This is the first identification of 3'-O-methylastilbin as a new flavonoid, as well as an active metabolite of astilbin in vivo, and is helpful for studying the kinetics of astilbin and its clinical applications.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.